HGH Fragment 176-191

HGH Fragment 176-191 is a synthetic peptide corresponding to amino acids 176 through 191 of the human growth hormone molecule — the C-terminal region specifically responsible for GH's lipolytic activity. This 16-amino-acid fragment retains the fat-metabolizing properties of full-length somatropin while lacking the domains required for GH receptor activation, IGF-1 stimulation, and systemic growth signaling. The result is a compound that promotes adipose tissue breakdown without the anabolic, insulin-antagonistic, or proliferative effects associated with full-spectrum HGH administration.

The fragment's mechanism of action is direct and targeted: it stimulates hormone-sensitive lipase (HSL) in adipocytes, accelerating the hydrolysis of stored triglycerides into free fatty acids and glycerol for oxidative metabolism. Crucially, it simultaneously inhibits lipogenesis — the enzymatic conversion of circulating glucose into new fat stores — creating a dual-action lipolytic environment. Research has demonstrated that Fragment 176-191 does not affect blood glucose levels, does not compete with insulin signaling, and does not stimulate long bone growth or organ hypertrophy. This selectivity makes it a fundamentally different research tool than full-length GH: it addresses the fat loss axis in isolation.

Researchers focused exclusively on fat reduction — without the broader systemic effects of full HGH — will find Fragment 176-191 the most targeted compound available for that purpose. It is commonly incorporated into cutting-phase research protocols alongside caloric deficit regimens, and pairs effectively with other lipolytic agents. It does not require the extended timelines of full GH protocols; measurable changes in fat oxidation markers have been observed within 4–6 weeks of consistent administration at standard research doses of 250–500mcg two to three times daily.

Reconstitution follows standard peptide protocol: add bacteriostatic water slowly against the vial wall, allow the lyophilized powder to dissolve without shaking, and refrigerate at 2–8°C. The reconstituted solution should be used within 21 days. Subcutaneous injection is the standard route, typically administered on an empty stomach (fasted state or at minimum 2–3 hours post-meal) to avoid insulin-mediated interference with the lipolytic mechanism. Many researchers dose upon waking and again mid-afternoon, timed around periods of low circulating insulin.